scholarly journals Chamomile Extract versus Clotrimazole Vaginal Cream in Treatment of Vulvovaginal Candidiasis: A Randomized Double-Blind Control Trial

2021 ◽  
Vol 24 (4) ◽  
pp. 191-195
Author(s):  
Zahra Shiravani ◽  
Tahereh Poordast ◽  
Shaghayegh Moradi Alamdarloo ◽  
Fateme sadat Najib ◽  
Fatemeh Hosseinzadeh ◽  
...  
Keyword(s):  
Vulvovaginal Candidiasis ◽  
Double Blind ◽  
Vaginal Cream

scholarly journals Comparing the Effect of Dill Seed Vaginal Cream, with a Persian Traditional Base, and 1% Clotrimazole Vaginal Cream on Vulvovaginal Candidiasis: A Double-Blind, Randomized Clinical Trial

2018 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Zohreh Sarhadinejad ◽  
Haleh Tajadini ◽  
Mojgan Tansaz ◽  
Abbas Bahrampour ◽  
Zarrin Sarhadynejad ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Vulvovaginal Candidiasis ◽  
Double Blind ◽  
Vaginal Cream

Effectiveness of Ageratina pichinchensis Extract in Patients with Vulvovaginal Candidiasis. A Randomized, Double-Blind, and Controlled Pilot Study

2017 ◽  
Vol 31 (6) ◽  
pp. 885-890 ◽  
Author(s):  
Ofelia Romero-Cerecero ◽  
Ana Laura Islas-Garduño ◽  
Alejandro Zamilpa ◽  
Jaime Tortoriello
Keyword(s):  
Pilot Study ◽  
Vulvovaginal Candidiasis ◽  
Double Blind

scholarly journals An Evaluation of Butoconazole Nitrate 2% Site Release®Vaginal Cream (Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis

2005 ◽  
Vol 13 (4) ◽  
pp. 197-206 ◽  
Author(s):  
Larry S. Seidman ◽  
Campbell K. Skokos
Keyword(s):  
Single Dose ◽  
Treatment Group ◽  
Adverse Events ◽  
Median Time ◽  
The United States ◽  
Vulvovaginal Candidiasis ◽  
Reinfection Rate ◽  
Vaginal Cream ◽  
Butoconazole Nitrate ◽  
Site Release

Background.It is estimated that as many as 13 million cases of vulvovaginal infection occur in the United States annually, the majority of which are the result ofCandida albicansinfection. The symptoms of vulvovaginal infections are often painful and distressing to the patient. The objective of this study was to compare the time to symptomatic relief of vulvovaginal candidiasis (VVC) with butoconazole nitrate 2% Site Release®vaginal cream (Gynazole-1®) and oral fluconazole 150 mg tablets (Diflucan®).Methods.This randomized, open-label, parallel study evaluated 181 female patients with moderate to severe symptoms of VVC. Patients were randomized to single-dose therapy with either butoconazole nitrate 2% Site Release®vaginal cream or fluconazole. The primary outcome measure was the time to onset of first relief of symptoms. Secondary measures included the time to overall relief of symptoms and the reinfection rate over the first 30 days following treatment. The overall safety of both products was investigated through the collection of adverse event reports.Results.The median time to first relief of symptoms occurred at 17.5 h for butoconazole patients as compared to 22.9 h for fluconazole patients (p< 0.001). The time at which 75% of patients experienced first relief of symptoms was 24.5 h versus 46.3 h for butoconazole and fluconazole, respectively (p< 0.001). By 12- and 24-h post-treatment, 44.4% and 72.8% of patients in the butoconazole treatment group reported first relief of symptoms versus 29.1% and 55.7% of patients in the fluconazole group (p= 0.044 andp= 0.024 respectively). In patients experiencing first relief of symptoms within 48 h of dosing, the median time to first relief of symptoms in the butoconazole treatment group was significantly shorter at 12.9 h compared to 20.7 h for the fluconazole treatment group (p= 0.048). There were no significant differences between the two groups with respect to time to total relief of symptoms or reoccurrence of infection within 30 days of treatment. Butoconazole therapy was shown to have fewer reported adverse events, including drug-related adverse events, than fluconazole therapy. Vulvovaginal pruritis and vulvovaginal burning were the most common drug-related adverse events attributed to butoconazole. Headache, diarrhea, nausea, upset stomach and skin sensitivity were the most common drugrelated adverse events attributable to fluconazole.Conclusions.Single-dose butoconazole nitrate 2% Site Release®vaginal cream provides statistically significant improvement in time to first relief of symptoms in the treatment of VVC compared to fluconazole. There is no difference between these two treatments with respect to total relief of symptoms or reinfection rate. Although there was no significant difference in the incidence of adverse events judged by the investigator to be treatment-related, butoconazole treatment did result in fewer patients experiencing adverse events than fluconazole.

scholarly journals Role of probiotics in lower reproductive tract infection in women of age group 18 to 45 years

2017 ◽  
Vol 6 (2) ◽  
pp. 671
Author(s):  
Rukshana Shamshu ◽  
Jayasree Vaman ◽  
Nirmala C.
Keyword(s):  
Bacterial Vaginosis ◽  
Lactobacillus Reuteri ◽  
Lactobacillus Rhamnosus ◽  
Vulvovaginal Candidiasis ◽  
Controlled Study ◽  
Control Group ◽  
P Value ◽  
Double Blind ◽  
Reproductive Tract Infection ◽  
Conventional Antibiotics

Background: This study has been designed to assess the effectiveness of the probiotic strains having Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in the management of lower genital infections (bacterial vaginosis and candidiasis) as an integral therapy with antibiotics.Methods: Double blind, randomized placebo controlled study in women between 18-45 years attending Sree Avittom Thirunal Hospital (SATH), Government Medical College, Thiruvananthapuram, India with symptoms of bacterial vaginosis and vulvovaginal candidiasis. Women giving consent were given probiotics along with conventional antibiotics and were followed up over a period of two months. Outcome is measured as percentage of women showing a score of less than 4 at the end of thirty days of treatment, and sixty days of treatment in the test and control group in the case of bacterial vaginosis and no discharge and absence of hyphae and pseudohyphae in wet smear and gram stain in case of candidiasis.Results: Out of 42 women studied, 32 had bacterial vaginosis and 10 had vulvovaginal candidiasis. 81.3% women with BV had a normal vaginal picture after sixty days of treatment as compared to placebo which was only 31.3%. The p value is 0.004 which is significant. In the treatment of VC, the percentage of women cured was the same in both probiotic and placebo group.Conclusions: In the treatment of bacterial vaginosis, addition of probiotics to the conventional antibiotics can improve the cure rate of bacterial vaginosis and reduce the rate of recurrences. In the treatment of vulvovaginal candidiasis, addition of probiotics to the conventional antifungal did not have a significant improvement.

Effect of Foeniculum vulgare (fennel) vaginal cream on vaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled trial

Maturitas ◽  
2016 ◽  
Vol 84 ◽  
pp. 75-80 ◽  
Author(s):  
Masomeh Yaralizadeh ◽  
Parvin Abedi ◽  
Shahnaz Najar ◽  
Foroogh Namjoyan ◽  
Amal Saki
Keyword(s):  
Postmenopausal Women ◽  
Controlled Trial ◽  
Vaginal Atrophy ◽  
Foeniculum Vulgare ◽  
Double Blind ◽  
Vaginal Cream

Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease

1992 ◽  
Vol 15 (11) ◽  
pp. 801-806 ◽  
Author(s):  
C. Nappi ◽  
Pietro Affinito ◽  
C. Di Carlo ◽  
G. Esposito ◽  
U. Montemagno
Keyword(s):  
Benign Breast Disease ◽  
Controlled Trial ◽  
Breast Disease ◽  
Double Blind ◽  
Vaginal Cream

scholarly journals The effect of curcumin-based and clotrimazole vaginal cream in the treatment of vulvovaginal candidiasis

2019 ◽  
Vol 8 (12) ◽  
pp. 3920
Author(s):  
Zahra Abbaspoor ◽  
Nilufar Abouali ◽  
Eskandar Moghimipour ◽  
AliZarei Mahmoudabadi ◽  
Foroogh Namjouyan
Keyword(s):  
Vulvovaginal Candidiasis ◽  
Vaginal Cream
Sign in / Sign up

Export Citation Format

Share Document